Biological and molecular characteristics of Mycobacterium tuberculosis clinical isolates with low-level resistance to isoniazid in Japan.
We reevaluated the BACTEC MGIT 960 antimicrobial susceptibility testing system (MGIT 960 AST) by using 1,112 isolates of Mycobacterium tuberculosis. When the results of MGIT 960 AST were compared with that of the proportion method using Ogawa medium (Ogawa PM), discrepant results were obtained for 30 strains with isoniazid, all resistant by MGIT 960 AST but susceptible by Ogawa PM. For 93% of the strains that produced discrepant results, the MIC was 0.4 or 0.8 microg/ml, showing resistance by the proportion method using Middlebrook agar plates. Furthermore, it was also established by analyses of the katG and inhA genes that strains resistant only by MGIT 960 AST have a low level of isoniazid (INH) resistance, indicating that MGIT 960 AST is a reliable method. Ninety-six strains were resistant to 0.1 microg/ml INH by MGIT 960 AST. When they were divided into three groups, Low-S (susceptible at 0.2 microg/ml), Low-R (resistant at 0.2 microg/ml), and High-R (resistant at 1.0 microg/ml), by Ogawa PM, 43.3% of the Low-S strains had mutations in the promoter region of inhA and no mutations were detected in katG codon 315, while 61.7% of the High-R strains had katG codon 315 mutations or a gross deletion of katG. These results suggest that mutations in inhA are associated with low-level resistance to INH and katG codon 315 mutations are associated with high-level resistance to INH. In addition, the analyses demonstrated some relationship of mutations in the inhA gene with ethionamide resistance for the Low-S strains, but not for the High-R strains.
Fukushima Laboratory, Nippon Becton Dickinson Diagnostic Systems, Tsuchifune, Fukushima 960-2152, Japan. abe_chiyoji@yahoo.co.jp
Chiyoji
C
Abe
Ikuo
I
Kobayashi
Satoshi
S
Mitarai
Masako
M
Wada
Yoshiko
Y
Kawabe
Tetsuya
T
Takashima
Katsuhiro
K
Suzuki
Li-Hwei
LH
Sng
Suxing
S
Wang
Hla Hla
HH
Htay
Hideo
H
Ogata
D000995:Antitubercular Agents / Q000494:pharmacology*; D001426:Bacterial Proteins / Q000235:genetics; D002374:Catalase / Q000235:genetics; D018389:Codon, Nonsense; D004269:DNA, Bacterial / Q000737:chemistry / Q000235:genetics; D024881:Drug Resistance, Bacterial; D005000:Ethionamide / Q000494:pharmacology; D017353:Gene Deletion; D006801:Humans; D007538:Isoniazid / Q000494:pharmacology*; D007564:Japan; D008826:Microbial Sensitivity Tests; D009154:Mutation; D020125:Mutation, Missense; D009169:Mycobacterium tuberculosis / Q000187:drug effects* / Q000302:isolation & purification*; D010088:Oxidoreductases / Q000235:genetics; D011401:Promoter Regions, Genetic; D014376:Tuberculosis / Q000382:microbiology*
D000995:Antitubercular Agents; D001426:Bacterial Proteins; D018389:Codon, Nonsense; D004269:DNA, Bacterial; D010088:Oxidoreductases; D002374:Catalase; C480353:katG protein, Mycobacterium tuberculosis; C085257:InhA protein, Mycobacterium; D005000:Ethionamide; D007538:Isoniazid